The clinical effect and tolerability of ezetimibe in high-risk patients managed in a specialty cardiovascular risk reduction clinic.

about

The clinical effect and tolerability of ezetimibe in high-risk patients managed in a specialty cardiovascular risk reduction clinic.

Item

http://www.wikidata.org/entity/Q36943340

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

The clinical effect and tolera ...... ascular risk reduction clinic.

@en

type

Item

label

The clinical effect and tolera ...... ascular risk reduction clinic.

@en

prefLabel

The clinical effect and tolera ...... ascular risk reduction clinic.

@en

P1476

The clinical effect and tolera ...... ascular risk reduction clinic.

@en

P2093

Andrea Opgenorth

http://www.w3.org/2001/XMLSchema#string

Dawna M Gilchrist

http://www.w3.org/2001/XMLSchema#string

Gabor T Gyenes

http://www.w3.org/2001/XMLSchema#string

Glen J Pearson

http://www.w3.org/2001/XMLSchema#string

Gordon A Francis

http://www.w3.org/2001/XMLSchema#string

Jacques S Romney

http://www.w3.org/2001/XMLSchema#string

P2860

Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia

The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

P304

939-945

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0828-282X(06)70313-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2006-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6819011

http://www.w3.org/2001/XMLSchema#string

P698

16971979

http://www.w3.org/2001/XMLSchema#string

P932

2570239

http://www.w3.org/2001/XMLSchema#string